Angle reports promising results from Parsortix study
Angle
14.71p
12:35 12/06/24
Angle, the AIM-listed liquid biopsy company which specialises in circulating tumour cell (CTC) solutions, has announced the results of a clinical study which show that its Parsortix system could be used to predict progression-free survival in patients with ovarian cancer.
FTSE AIM All-Share
784.06
12:35 12/06/24
Support Services
11,407.73
12:34 12/06/24
The peer-reviewed publication studied the use of Parsortix to identify markers present in CTCs harvested from metastatic mutant-p53 platinum-resistant ovarian cancer (PROC) patients.
The study analysed 474 blood samples from 123 PROC patients over a two-and-a-half-year period during treatment until disease progression.
Angle's chief scientific officer Karen Miller said the paper "demonstrates the potential utility of molecular characterisation of CTCs enriched using the Parsortix system in monitoring ovarian cancer patients throughout their treatment and during follow-up".
She said: "The scale of this study, both in terms of numbers of patients and timescale of follow-up, is particularly important. It clearly demonstrates how use of the Parsortix system in cancer trials could in the future enable our pharma customers to gain an early understanding of how patients are responding to their drug."
The stock was up 1.5% at 23.59p by 1239 BST.